ArticleEuropean journal of haematology2019
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Article in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05439538 (Serum Neutrophil Gelatinase-associated Lipocalin), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serum Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Predictor of Renal Injury in Patients With Multiple Myeloma
Who cites it
20 citing papers in PubMed.
- Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.Science translational medicine · 2026Article
- Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.European journal of haematology · 2026Article
- Article
- Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma.Diagnostics (Basel, Switzerland) · 2025Review
- Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study).Frontiers in oncology · 2025Article
- Article
- Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.Nature communications · 2024Article
- Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.Bone marrow transplantation · 2024Article
- Scalable and interpretable alternative to chart review for phenotype evaluation using standardized structured data from electronic health records.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Exploiting big data survival information to unify risk-stratification related, adaptive immune receptor parameters for multiple myeloma.Genes and immunity · 2023Article
- Article
- Profile and outcome of multiple myeloma with and without HIV treated at a tertiary hospital in KwaZulu-Natal, South Africa.PloS one · 2023Article
- Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.Leukemia · 2022Review
- Renal Impairment Detectors: IGFBP-7 and NGAL as Tubular Injury Markers in Multiple Myeloma Patients.Medicina (Kaunas, Lithuania) · 2021Article
- Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy.Cancer biology & therapy · 2021Article
- Sequencing multiple myeloma therapies with and after antibody therapies.Hematology. American Society of Hematology. Education Program · 2020Review
- Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.Oncology research and treatment · 2020Article
- Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.European journal of haematology · 2019Article
- Socioeconomic Disparities in Multiple Myeloma Survival in New South Wales Australia: A Population-Based Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThis study aimed to provide real-world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death.
methodsThe study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date.
resultsData from 786 patients were reviewed. At the time of death, 37% of patients were receiving active treatment, 12% were in a treatment-free interval and 51% were receiving only supportive care. Death before and during active first-line treatment was not uncommon (6% and 24% of patients, respectively) but these deaths were often not solely due to disease progression; factors such as renal failure and infection frequently played a role (in 30% and 20% of patients at first-line, respectively). Most deaths at later lines were due to progressive disease. Cox model results suggested that early deaths were associated with advanced disease stage, high-risk cytogenetics and poor response and relapse profiles.
conclusionsThese real-world data could be used to help develop strategies for improving survival in patients with MM and to support management tailored to the stage of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.